CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

June 14, 2024

Study Completion Date

October 31, 2025

Conditions
Desmoplastic Small Round Cell Tumor
Interventions
DRUG

Ramucirumab

Administered IV

DRUG

Cyclophosphamide

Administered orally

DRUG

Vinorelbine

Administered IV

Trial Locations (22)

165

Ospedale Pediatrico Bambino Gesù, Rome

3052

Royal Children's Hospital, Parkville

10065

Memorial Sloan Kettering Cancer Center, New York

19104

Children's Hospital of Philadelphia (CHOP), Philadelphia

20010

Children's National Medical Center, Washington D.C.

20089

Humanitas, Rozzano

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20251

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

35128

Azienda Ospedaliera di Padova, Padua

41013

Hospital Universitario Virgen Del Rocio, Seville

45122

Universitaetsklinikum Essen, Essen

63110

Washington University, St Louis

79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital of Los Angeles, Los Angeles

104-0045

National Cancer Center Hospital, Chuo-ku

812-8582

Kyushu University Hospital, Fukuoka

08035

Hospital Universitari Vall d'Hebron, Barcelona

NW1 2PG

University College London Hospital, London

SM2 5PT

Royal Marsden Hospital (Sutton), London

M13 9WL

Royal Manchester Children's Hospital, Manchester

M20 4BX

The Christie, Manchester

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04145349 - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Biotech Hunter | Biotech Hunter